| Synonyms: | |
| Status: | Phase 2 |
| Entry Type: | Antibody |
| Molecule Category: | UNKNOWN |
| UNII: | FE7L22H028 |
Pharmacology
| Action | Mechanism of Action | Reference |
|---|---|---|
| INHIBITOR | Cytotoxic T-lymphocyte protein 4 inhibitor | Other |
Indications
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Hemangiosarcoma | 2 | D006394 | ClinicalTrials |
| Carcinoma, Non-Small-Cell Lung | 2 | D002289 | ClinicalTrials |
| Sarcoma | 2 | D012509 | ClinicalTrials |
| Uterine Cervical Neoplasms | 2 | D002583 | ClinicalTrials |
| Urinary Bladder Neoplasms | 2 | D001749 | ClinicalTrials |
| Diffuse Intrinsic Pontine Glioma | 1 | D000080443 | ClinicalTrials |
| Carcinoma, Pancreatic Ductal | 1 | D021441 | ClinicalTrials |
| Neoplasms | 1 | D009369 | ClinicalTrials |
Cross References
| Resources | Reference |
|---|---|
| ChEMBL | CHEMBL4297876 |
| FDA SRS | FE7L22H028 |
CONTENTS